Table 3.
Comparison of the secondary end-points
|
Before treatment
|
After treatment
|
|||||
|
UTI group (n = 91)
|
Placebo group (n = 90)
|
P value
|
UTI group (n = 91)
|
Placebo group (n = 90)
|
P value
|
|
| Inflammatory cytokine, mean ± SD | ||||||
| TNF-α (pg/mL) | 77.28 ± 19.43 | 76.91 ± 18.27 | 0.895 | 29.67 ± 11.19 | 43.17 ± 12.08 | < 0.001 |
| IL-6 (pg/mL) | 89.37 ± 16.28 | 87.91 ± 16.74 | 0.553 | 50.18 ± 12.24 | 66.35 ± 14.26 | < 0.001 |
| Coagulation function, mean ± SD | ||||||
| PT (s) | 21.05 ± 3.44 | 20.62 ± 3.19 | 0.385 | 12.16 ± 2.84 | 16.71 ± 3.15 | < 0.001 |
| APTT (s) | 39.22 ± 4.26 | 40.15 ± 4.39 | 0.150 | 32.26 ± 3.73 | 37.25 ± 4.02 | < 0.001 |
| D-D (mg/L) | 4.26 ± 1.12 | 4.33 ± 1.27 | 0.694 | 1.75 ± 0.59 | 2.94 ± 0.79 | < 0.001 |
| FIB (g/L) | 1.07 ± 0.23 | 1.12 ± 0.26 | 0.172 | 3.46 ± 0.60 | 3.28 ± 0.55 | 0.037 |
| Infection index levels, mean ± SD | ||||||
| CRP (mg/L) | 31.29 ± 4.16 | 30.98 ± 4.07 | 0.613 | 5.19 ± 0.97 | 8.34 ± 1.33 | < 0.001 |
| PCT (ng/L) | 2.05 ± 0.21 | 2.10± 0.19 | 0.095 | 0.75 ± 0.23 | 0.82 ± 0.38 | 0.135 |
| WBC (× 109/L) | 18.05 ± 9.11 | 17.56 ± 8.97 | 0.716 | 12.74 ± 6.41 | 15.19 ± 7.29 | 0.017 |
| Liver function index levels, mean ± SD | ||||||
| ALT (U/L) | 32.20 ± 3.74 | 33.15 ± 3.68 | 0.087 | 48.19 ± 4.27 | 53.11 ± 4.53 | < 0.001 |
| AST (U/L) | 34.17 ± 2.83 | 34.42 ± 2.99 | 0.564 | 49.67 ± 3.88 | 50.27 ± 4.19 | 0.230 |
| Renal function index levels, mean ± SD | ||||||
| Scr | 81.26 ± 9.91 | 79.64 ± 9.12 | 0.254 | 84.22 ± 10.16 | 105.42 ± 11.20 | < 0.001 |
| BUN | 5.37 ± 1.94 | 5.19 ± 1.73 | 0.511 | 8.06 ± 2.99 | 10.19 ± 3.28 | < 0.001 |
TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; APTT: Activated partial thromboplastin time; PT: Prothrombin time; FIB: Fibrinogen; CRP: C-reactive protein; PCT: Procalcitonin; WBC: White blood cell; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; UTI: Ulinastatin.